Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of invasive fungal infections. It is currently only licensed for use in children greater than 12 years of age. Absorption of the oral formulation is unpredictable and affected by mucositis and concomitant medications. We reviewed studies of posaconazole use in children younger than 12 years in relation to attainment of target serum concentrations.
From the *Infectious Diseases and Australian Paediatric Pharmacology Research Unit, The Royal Children’s Hospital Melbourne; and †Murdoch Children’s Research Institute; and ‡Department of Paediatrics, The University of Melbourne, Victoria, Australia.
Accepted for publication October 4, 2014.
The authors have no funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Amanda Gwee, FRACP, Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, 50 Flemington Rd, Parkville, Victoria 3052, Australia. E-mail: email@example.com.